S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Chuck Todd leaving NBC political panel show 'Meet the Press'
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Chuck Todd leaving NBC political panel show 'Meet the Press'
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Chuck Todd leaving NBC political panel show 'Meet the Press'
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Chuck Todd leaving NBC political panel show 'Meet the Press'
NASDAQ:BCAB

BioAtla (BCAB) Stock Forecast, Price & News

$3.47
+0.15 (+4.52%)
(As of 06/2/2023 ET)
Compare
Today's Range
$3.25
$3.50
50-Day Range
$2.35
$3.87
52-Week Range
$2.23
$12.15
Volume
402,031 shs
Average Volume
299,047 shs
Market Capitalization
$165.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.67

BioAtla MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
351.5% Upside
$15.67 Price Target
Short Interest
Healthy
7.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.22mentions of BioAtla in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$148,776 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.48) to ($2.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

229th out of 983 stocks

Biological Products, Except Diagnostic Industry

28th out of 164 stocks


BCAB stock logo

About BioAtla (NASDAQ:BCAB) Stock

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Receive BCAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter.

BCAB Stock News Headlines

Instantly Find Hidden Trade Opportunities
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Where BioAtla Stands With Analysts
Instantly Find Hidden Trade Opportunities
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
H.C. Wainwright Keeps Their Buy Rating on BioAtla (BCAB)
BioAtla (BCAB) Receives a Buy from JMP Securities
BioAtla (BCAB) Receives a Buy from BTIG
Bioatla (BCAB) Earnings Dates & Reports
BioAtla (NASDAQ:BCAB) Price Target Cut to $13.00
See More Headlines

BCAB Price History

BCAB Company Calendar

Last Earnings
3/23/2023
Today
6/04/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCAB
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.67
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+351.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-106,480,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$250,000.00
Book Value
$3.28 per share

Miscellaneous

Free Float
40,613,000
Market Cap
$165.41 million
Optionable
Not Optionable
Beta
0.27

Key Executives

  • Dr. Jay M. Short Ph.D. (Age 65)
    Co-Founder, CEO & Chairman
    Comp: $1.02M
  • Mr. Scott Andrew SmithMr. Scott Andrew Smith (Age 61)
    Pres & Director
    Comp: $798.89k
  • Mr. Richard A. WaldronMr. Richard A. Waldron (Age 69)
    Chief Financial Officer
    Comp: $593.51k
  • Dr. Eric L. Sievers M.D. (Age 59)
    Chief Medical Officer
    Comp: $552.62k
  • Mr. Christian VasquezMr. Christian Vasquez (Age 48)
    VP of Fin., Corp. Controller & Sec.
    Comp: $345.88k
  • Mr. Philippe Martin (Age 47)
    Chief Clinical Devel. & Operations
  • Lisa M. Pelton
    Accounting Mang.
  • Ms. Susie Melody
    Sr. VP of HR
  • Dr. Cathy Chang Ph.D.
    Sr. VP of R&D
  • Ms. Monica Sullivan
    Sr. VP of Intellectual Property & Contracts













BCAB Stock - Frequently Asked Questions

Should I buy or sell BioAtla stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCAB shares.
View BCAB analyst ratings
or view top-rated stocks.

What is BioAtla's stock price forecast for 2023?

6 brokerages have issued twelve-month price objectives for BioAtla's stock. Their BCAB share price forecasts range from $8.00 to $25.00. On average, they anticipate the company's stock price to reach $15.67 in the next twelve months. This suggests a possible upside of 351.5% from the stock's current price.
View analysts price targets for BCAB
or view top-rated stocks among Wall Street analysts.

How have BCAB shares performed in 2023?

BioAtla's stock was trading at $8.25 at the beginning of the year. Since then, BCAB shares have decreased by 57.9% and is now trading at $3.47.
View the best growth stocks for 2023 here
.

Are investors shorting BioAtla?

BioAtla saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 3,590,000 shares, a decrease of 5.0% from the April 30th total of 3,780,000 shares. Based on an average daily trading volume, of 499,900 shares, the days-to-cover ratio is currently 7.2 days.
View BioAtla's Short Interest
.

When is BioAtla's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our BCAB earnings forecast
.

How were BioAtla's earnings last quarter?

BioAtla, Inc. (NASDAQ:BCAB) issued its earnings results on Thursday, March, 23rd. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.11.

What ETFs hold BioAtla's stock?

ETFs with the largest weight of BioAtla (NASDAQ:BCAB) stock in their portfolio include Formidable ETF (FORH).ALPS Medical Breakthroughs ETF (SBIO).

When did BioAtla IPO?

(BCAB) raised $150 million in an IPO on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO.

What is BioAtla's stock symbol?

BioAtla trades on the NASDAQ under the ticker symbol "BCAB."

Who are BioAtla's major shareholders?

BioAtla's stock is owned by a number of retail and institutional investors. Top institutional investors include Candriam S.C.A. (3.29%), Wasatch Advisors LP (2.66%), BlackRock Inc. (2.07%), Deutsche Bank AG (1.45%), Vontobel Holding Ltd. (1.16%) and Sectoral Asset Management Inc. (1.14%). Insiders that own company stock include Christian Vasquez, Cormorant Asset Management, Lp, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron, Scott Andrew Smith and Sylvia Mcbrinn.
View institutional ownership trends
.

How do I buy shares of BioAtla?

Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioAtla's stock price today?

One share of BCAB stock can currently be purchased for approximately $3.47.

How much money does BioAtla make?

BioAtla (NASDAQ:BCAB) has a market capitalization of $165.41 million and generates $250,000.00 in revenue each year. The company earns $-106,480,000.00 in net income (profit) each year or ($2.67) on an earnings per share basis.

How can I contact BioAtla?

The official website for the company is www.bioatla.com. The company can be reached via phone at 858-558-0708 or via email at investors@bioatla.com.

This page (NASDAQ:BCAB) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -